

Ref: BF/COR/CM-N1
Date: August 20, 2026

The General Manager,
Pakistan Stock Exchange Limited,
Stock Exchange Building,
Stock Exchange Road,
Karachi.

INFORMATION REGARDING INTRODUCTION OF CONTINUOUS GLUCOSE MONITORING (CGM) DEVICES

Dear Sir,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1(a) of the PSX Rule Book, we hereby convey the following information:

With reference to a recent product launch related coverage on digital media and in response to queries received from shareholders, BF Biosciences Limited ("the Company") would like to provide the following information for the general public as per the regulations.

The Company has recently launched Continuous Glucose Monitoring (CGM) devices in Pakistan in collaboration with SIBIONICS, China, a medical technology company focused on continuous glucose monitoring and digital health solutions, under the brand name of Sibionics CGM.

Founded in 2015, SIBIONICS has established a significant global presence in CGM technology. According to information published by SIBIONICS, its products and services are available in more than 100 countries, serving over 4 million users globally.

CGM is an emerging technology in the management of diabetes that enables continuous monitoring of glucose levels and trends. It provides patients and healthcare professionals with insights into glucose patterns and the impact of food, physical activity and other lifestyle factors, thereby supporting more informed diabetes and lifestyle management.

The launch of Sibionics CGM is aligned with BF Biosciences' strategy of developing a more integrated approach to metabolic care. The technology is intended to complement and support patients being managed with the Company's existing metabolic portfolio, including Ferulin® (Insulin), Sematide® (Semaglutide) and Zeptide® (Tirzepatide), as clinically appropriate and under the guidance of healthcare professionals.

☐ **Head Office/Biotech Factory:**

5 - KM, Sundar Raiwind Road
Raiwind (55150), Pakistan
Tel: (+92 42) 3602 6700
Fax: (+92 42) 3602 6701-02

☐ **Registered Office:**

197 - A, The Mall, Rawalpindi
(46000), Pakistan
Tel: (+92 51) 4252 155-57
Fax: (+92 51) 4252 153

☐ **Lahore Sales Office:**

43 - Al Noor Building, Bank
Square, The Mall, Lahore
(54000), Pakistan
Tel: (+92 42) 3735 8194
Fax: (+92 42) 3731 3680

☐ **Karachi Sales Office:**

House No. 9, Maqbool Cooperative
Housing Society, Shahr-e-Faisal
Karachi (75350), Pakistan
Tel: (+92 21) 3438 6852
Fax: (+92 21) 3438 6754


Through the integration of medicines, devices and disease awareness initiatives i.e. SlimPossible, BF Biosciences aims to support a more comprehensive approach towards the management of diabetes, obesity and related metabolic conditions, consistent with the Company's purpose of Putting Patients First.

The Company remains committed to keeping its shareholders and the Pakistan Stock Exchange informed of any material developments in accordance with applicable laws and regulations.

You are requested to please disseminate the above information to TREC Holders of the Exchange accordingly.

Thank you.

Yours truly,



Abdur Rehman
Company Secretary



CC: Director Enforcement – Securities and Exchange Commission of Pakistan.

☐ **Head Office/Biotech Factory:**

5 - KM, Sundar Raiwind Road
Raiwind (55150), Pakistan
Tel: (+92 42) 3602 6700
Fax: (+92 42) 3602 6701-02

☐ **Registered Office:**

197 - A, The Mall, Rawalpindi
(46000), Pakistan
Tel: (+92 51) 4252 155-57
Fax: (+92 51) 4252 153

☐ **Lahore Sales Office:**

43 - Al Noor Building, Bank
Square, The Mall, Lahore
(54000), Pakistan
Tel: (+92 42) 3735 8194
Fax: (+92 42) 3731 3680

☐ **Karachi Sales Office:**

House No. 9, Maqbool Cooperative
Housing Society, Shahr-e-Faisal
Karachi (75350), Pakistan
Tel: (+92 21) 3438 6852
Fax: (+92 21) 3438 6754